Abstract
IDN-6556 is a lead compound from a class of small-molecule caspase protease inhibitors, and is currently under development by Idun as a potential treatment for acute alcoholic and infectious hepatitis. In October 2003, a phase II trial of IDN-6556 began in 100 patients undergoing liver transplantation.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1198-1204 |
| Number of pages | 7 |
| Journal | Current Opinion in Investigational Drugs |
| Volume | 5 |
| Issue number | 11 |
| State | Published - Nov 2004 |
| Externally published | Yes |
ASJC Scopus subject areas
- Pharmacology
- Drug Discovery